- Home
- TTGT vs BCAX Comparison
TTGT vs BCAX Comparison
Compare TTGT & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- BCAX
- Stock Information
- Founded
- TTGT 1999
- BCAX 2018
- Country
- TTGT United States
- BCAX United States
- Employees
- TTGT N/A
- BCAX N/A
- Industry
- TTGT Telecommunications Equipment
- BCAX
- Sector
- TTGT Telecommunications
- BCAX
- Exchange
- TTGT Nasdaq
- BCAX NYSE
- Market Cap
- TTGT 561.6M
- BCAX 670.9M
- IPO Year
- TTGT 2007
- BCAX 2024
- Fundamental
- Price
- TTGT $8.31
- BCAX $12.97
- Analyst Decision
- TTGT Buy
- BCAX Buy
- Analyst Count
- TTGT 7
- BCAX 7
- Target Price
- TTGT $26.29
- BCAX $29.67
- AVG Volume (30 Days)
- TTGT 389.9K
- BCAX 586.0K
- Earning Date
- TTGT 05-20-2025
- BCAX 05-20-2025
- Dividend Yield
- TTGT N/A
- BCAX N/A
- EPS Growth
- TTGT N/A
- BCAX N/A
- EPS
- TTGT N/A
- BCAX N/A
- Revenue
- TTGT $260,750,999.00
- BCAX N/A
- Revenue This Year
- TTGT $44.88
- BCAX N/A
- Revenue Next Year
- TTGT N/A
- BCAX N/A
- P/E Ratio
- TTGT N/A
- BCAX N/A
- Revenue Growth
- TTGT 31.84
- BCAX N/A
- 52 Week Low
- TTGT $6.95
- BCAX $8.91
- 52 Week High
- TTGT $35.10
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- TTGT 41.65
- BCAX N/A
- Support Level
- TTGT $7.80
- BCAX N/A
- Resistance Level
- TTGT $8.55
- BCAX N/A
- Average True Range (ATR)
- TTGT 0.58
- BCAX 0.00
- MACD
- TTGT 0.30
- BCAX 0.00
- Stochastic Oscillator
- TTGT 73.12
- BCAX 0.00
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.